Lariva Business

Lariva Blog

Menu
  • Privacy Policy
  • Tech Sharing
  • animate sharing
  • Science Sharing
  • Happening
Menu

Omeros sold ophthalmic surgery products to Reina with us $126 million in cash

Posted on December 25, 2021December 25, 2021 by William

Seattle biotechnology company Omeros closed a deal Thursday to sell the product omidria for ophthalmic surgery to Rayner surgery group. The UK based Rayner acquired the omidria franchise for us $126 million.
As part of the deal, Omeros is eligible for a $200 million commercial milestone payment for FDA approved products for eye flushing during cataract surgery or lens replacement. According to a statement, together with royalties, the deal is worth more than $1 billion.
Omedra generated $30 million in revenue for omros in the third fiscal year of fiscal quarter 2021.
This fall, the FDA told Omeros that it needed more information before considering approving narsoplimad. Narsoplimad, a major clinical compound in biotechnology, is being tested for a rare coagulation disorder, which has led to a sharp decline in its inventory. As of the end of September, Omeros reported that it had $50.4 million in cash, cash equivalents and short-term investments available for operation.

Recent Posts

  • Microsoft confirms that the slowdown in office and windows recruitment is the latest sign of economic caution
  • Color vector display controller makes arcade classic return to life
  • Did Deku leave the U.A. at my hero college?
  • Pacific Northwest National Laboratory cooperates with the US space force to train cyber security personnel
  • Geothermal system is a real gold mine
©2022 Lariva Business | Design: Newspaperly WordPress Theme